Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hemostatics | 5 | 2020 | 142 | 2.51 | Why? |
| Plant Extracts | 8 | 2020 | 1514 | 2.28 | Why? |
| Hematopoiesis | 2 | 2020 | 168 | 0.95 | Why? |
| Leukemia, Myeloid, Acute | 5 | 2019 | 676 | 0.92 | Why? |
| Phytoestrogens | 1 | 2020 | 12 | 0.87 | Why? |
| Receptor, PAR-1 | 1 | 2020 | 24 | 0.86 | Why? |
| Mucositis | 1 | 2020 | 40 | 0.84 | Why? |
| Erythrocyte Aggregation | 1 | 2019 | 15 | 0.79 | Why? |
| Chromosomes, Human, Pair 16 | 1 | 2018 | 11 | 0.76 | Why? |
| Translocation, Genetic | 1 | 2018 | 40 | 0.74 | Why? |
| Losartan | 1 | 2019 | 86 | 0.73 | Why? |
| HMGB1 Protein | 1 | 2021 | 223 | 0.73 | Why? |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2019 | 314 | 0.72 | Why? |
| Superior Sagittal Sinus | 1 | 2016 | 2 | 0.69 | Why? |
| Lateral Sinus Thrombosis | 1 | 2016 | 11 | 0.69 | Why? |
| Estrogens | 1 | 2020 | 252 | 0.67 | Why? |
| Retinal Vein Occlusion | 1 | 2019 | 129 | 0.65 | Why? |
| Doxorubicin | 1 | 2019 | 313 | 0.64 | Why? |
| Chromosomes, Human, Pair 3 | 1 | 2018 | 195 | 0.63 | Why? |
| Off-Label Use | 1 | 2020 | 553 | 0.60 | Why? |
| Antithrombins | 1 | 2019 | 353 | 0.58 | Why? |
| Renin-Angiotensin System | 3 | 2020 | 3661 | 0.57 | Why? |
| Phytotherapy | 2 | 2020 | 743 | 0.57 | Why? |
| Platelet Activation | 1 | 2019 | 660 | 0.56 | Why? |
| Anastomosis, Surgical | 1 | 2015 | 169 | 0.54 | Why? |
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 520 | 0.52 | Why? |
| Bronchi | 1 | 2020 | 1048 | 0.50 | Why? |
| Lipid Metabolism | 1 | 2017 | 572 | 0.46 | Why? |
| Multiple Myeloma | 2 | 2019 | 1064 | 0.46 | Why? |
| Burns | 1 | 2018 | 466 | 0.45 | Why? |
| Immune System | 1 | 2020 | 1479 | 0.42 | Why? |
| Microvessels | 1 | 2015 | 490 | 0.42 | Why? |
| Sinus Thrombosis, Intracranial | 1 | 2016 | 550 | 0.41 | Why? |
| Hematologic Diseases | 1 | 2017 | 614 | 0.40 | Why? |
| Anti-Infective Agents | 1 | 2020 | 1766 | 0.36 | Why? |
| Klinefelter Syndrome | 1 | 2007 | 21 | 0.36 | Why? |
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2007 | 37 | 0.35 | Why? |
| Asymptomatic Diseases | 1 | 2020 | 3444 | 0.34 | Why? |
| Epithelial Cells | 1 | 2020 | 3508 | 0.34 | Why? |
| Spleen | 1 | 2010 | 877 | 0.31 | Why? |
| Immunization, Passive | 3 | 2021 | 10067 | 0.31 | Why? |
| Antineoplastic Agents | 2 | 2019 | 3550 | 0.31 | Why? |
| Gene Regulatory Networks | 2 | 2020 | 820 | 0.27 | Why? |
| Thrombophilia | 2 | 2020 | 1935 | 0.23 | Why? |
| Turkey | 5 | 2021 | 3937 | 0.23 | Why? |
| Receptor, IGF Type 2 | 1 | 2020 | 6 | 0.22 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.22 | Why? |
| Venous Thrombosis | 1 | 2016 | 2739 | 0.22 | Why? |
| Stomatitis | 1 | 2020 | 57 | 0.21 | Why? |
| Inflammation | 2 | 2020 | 13255 | 0.20 | Why? |
| Hemorheology | 1 | 2019 | 17 | 0.20 | Why? |
| Gene Expression Regulation, Leukemic | 1 | 2019 | 31 | 0.20 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.20 | Why? |
| Administration, Topical | 1 | 2020 | 272 | 0.19 | Why? |
| Consolidation Chemotherapy | 1 | 2018 | 41 | 0.19 | Why? |
| Hematopoietic Stem Cell Mobilization | 1 | 2019 | 73 | 0.19 | Why? |
| Hydrazines | 1 | 2019 | 68 | 0.19 | Why? |
| Philadelphia Chromosome | 1 | 2018 | 38 | 0.19 | Why? |
| Benzoates | 1 | 2019 | 102 | 0.19 | Why? |
| Cytarabine | 1 | 2018 | 64 | 0.18 | Why? |
| ErbB Receptors | 1 | 2020 | 320 | 0.18 | Why? |
| Hemorrhage | 1 | 2010 | 3013 | 0.18 | Why? |
| Disease Transmission, Infectious | 1 | 2021 | 9044 | 0.17 | Why? |
| Protein-Tyrosine Kinases | 1 | 2019 | 158 | 0.17 | Why? |
| Myelodysplastic Syndromes | 1 | 2020 | 261 | 0.17 | Why? |
| Mean Platelet Volume | 1 | 2019 | 203 | 0.17 | Why? |
| Gene Expression Regulation | 2 | 2020 | 4020 | 0.17 | Why? |
| Endothelium, Vascular | 2 | 2020 | 1751 | 0.17 | Why? |
| Genome, Human | 1 | 2020 | 400 | 0.16 | Why? |
| Wound Healing | 1 | 2020 | 424 | 0.16 | Why? |
| Hematopoietic Stem Cell Transplantation | 2 | 2021 | 2426 | 0.16 | Why? |
| Helicobacter Infections | 1 | 2019 | 216 | 0.15 | Why? |
| Liver | 1 | 2010 | 4007 | 0.15 | Why? |
| Obesity | 1 | 2017 | 7388 | 0.15 | Why? |
| Helicobacter pylori | 1 | 2019 | 262 | 0.15 | Why? |
| Leukemic Infiltration | 1 | 1995 | 9 | 0.15 | Why? |
| Gingiva | 1 | 1995 | 34 | 0.15 | Why? |
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2019 | 645 | 0.14 | Why? |
| Humans | 37 | 2021 | 930598 | 0.14 | Why? |
| Graft vs Host Disease | 1 | 2019 | 501 | 0.14 | Why? |
| Leukemia, Promyelocytic, Acute | 1 | 1995 | 60 | 0.14 | Why? |
| Linear Models | 1 | 2020 | 1914 | 0.13 | Why? |
| Cell Survival | 1 | 2019 | 1581 | 0.13 | Why? |
| Erythrocytes | 1 | 2019 | 617 | 0.12 | Why? |
| Stem Cell Transplantation | 1 | 2018 | 531 | 0.12 | Why? |
| Iron | 1 | 2019 | 619 | 0.12 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.12 | Why? |
| Platelet Count | 1 | 2019 | 1381 | 0.12 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.11 | Why? |
| Cluster Analysis | 1 | 2020 | 3001 | 0.11 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.11 | Why? |
| ABO Blood-Group System | 1 | 2020 | 995 | 0.11 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.10 | Why? |
| Pyrimidines | 1 | 2018 | 1557 | 0.10 | Why? |
| Cell Line, Tumor | 1 | 2019 | 3608 | 0.10 | Why? |
| Remission Induction | 3 | 2019 | 950 | 0.10 | Why? |
| Multiple Organ Failure | 1 | 2020 | 1724 | 0.10 | Why? |
| Drug Resistance, Bacterial | 1 | 2019 | 1414 | 0.09 | Why? |
| Protein Kinase Inhibitors | 1 | 2019 | 1585 | 0.09 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.09 | Why? |
| Pyrazoles | 1 | 2019 | 1791 | 0.09 | Why? |
| Apoptosis | 1 | 2019 | 2335 | 0.09 | Why? |
| Fatal Outcome | 1 | 2018 | 3438 | 0.09 | Why? |
| Periodicals as Topic | 1 | 2021 | 1492 | 0.09 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.09 | Why? |
| Models, Animal | 1 | 2010 | 788 | 0.08 | Why? |
| Male | 21 | 2021 | 367725 | 0.08 | Why? |
| Homozygote | 1 | 2007 | 230 | 0.08 | Why? |
| Rabbits | 1 | 2010 | 1171 | 0.08 | Why? |
| Disease Susceptibility | 1 | 2020 | 4002 | 0.08 | Why? |
| Blast Crisis | 1 | 2006 | 41 | 0.08 | Why? |
| Headache | 1 | 2016 | 2257 | 0.08 | Why? |
| Transplantation, Homologous | 2 | 2019 | 757 | 0.08 | Why? |
| Leukemia, Myeloid | 1 | 2006 | 76 | 0.08 | Why? |
| RNA, Messenger | 1 | 2020 | 5131 | 0.07 | Why? |
| Activated Protein C Resistance | 1 | 2004 | 7 | 0.07 | Why? |
| Middle Aged | 15 | 2021 | 270681 | 0.07 | Why? |
| Protein C Inhibitor | 1 | 2004 | 1 | 0.07 | Why? |
| Transplant Recipients | 1 | 2021 | 4982 | 0.07 | Why? |
| Point Mutation | 1 | 2007 | 481 | 0.07 | Why? |
| Factor V | 1 | 2004 | 52 | 0.07 | Why? |
| Apolipoproteins | 1 | 2004 | 33 | 0.07 | Why? |
| Hemostasis | 1 | 2010 | 811 | 0.07 | Why? |
| Tuberculosis | 1 | 2020 | 2895 | 0.07 | Why? |
| Gastrointestinal Diseases | 1 | 2019 | 2580 | 0.06 | Why? |
| Peptidyl-Dipeptidase A | 2 | 2020 | 9659 | 0.06 | Why? |
| Case-Control Studies | 2 | 2020 | 17671 | 0.06 | Why? |
| Aged | 13 | 2021 | 215776 | 0.06 | Why? |
| Sepsis | 1 | 2020 | 3517 | 0.06 | Why? |
| Arterial Occlusive Diseases | 1 | 2007 | 363 | 0.06 | Why? |
| Partial Thromboplastin Time | 1 | 2004 | 436 | 0.06 | Why? |
| Prognosis | 3 | 2020 | 32490 | 0.06 | Why? |
| Serum Amyloid A Protein | 1 | 2004 | 211 | 0.06 | Why? |
| Signal Transduction | 1 | 2019 | 7207 | 0.06 | Why? |
| Testosterone | 1 | 2007 | 596 | 0.06 | Why? |
| Retrospective Studies | 7 | 2021 | 105322 | 0.06 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.06 | Why? |
| Cytokines | 2 | 2020 | 15010 | 0.06 | Why? |
| Synovial Fluid | 1 | 2001 | 64 | 0.06 | Why? |
| Adult | 14 | 2021 | 244371 | 0.05 | Why? |
| Biomedical Research | 1 | 2021 | 5270 | 0.05 | Why? |
| Animals | 3 | 2017 | 78931 | 0.05 | Why? |
| Behcet Syndrome | 1 | 2001 | 136 | 0.05 | Why? |
| Gene Expression Regulation, Neoplastic | 1 | 2006 | 1014 | 0.05 | Why? |
| Female | 14 | 2021 | 380317 | 0.05 | Why? |
| Physicians | 1 | 2018 | 4214 | 0.05 | Why? |
| Young Adult | 6 | 2020 | 93724 | 0.05 | Why? |
| Induction Chemotherapy | 1 | 2019 | 149 | 0.05 | Why? |
| Respiration, Artificial | 2 | 2020 | 22116 | 0.04 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.04 | Why? |
| Urinary Retention | 1 | 1996 | 35 | 0.04 | Why? |
| Transplantation Conditioning | 1 | 2019 | 323 | 0.04 | Why? |
| Anti-Bacterial Agents | 1 | 2019 | 10083 | 0.04 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.04 | Why? |
| Treatment Outcome | 3 | 2019 | 51732 | 0.04 | Why? |
| Cohort Studies | 2 | 2019 | 36005 | 0.04 | Why? |
| Risk Factors | 3 | 2020 | 71621 | 0.04 | Why? |
| Body Temperature | 1 | 2020 | 875 | 0.03 | Why? |
| Prostate | 1 | 1996 | 283 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.03 | Why? |
| Prospective Studies | 1 | 2019 | 43301 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2018 | 1654 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2021 | 4260 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2019 | 3395 | 0.03 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.03 | Why? |
| Microbial Sensitivity Tests | 1 | 2019 | 2886 | 0.02 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.02 | Why? |
| Adolescent | 2 | 2019 | 86841 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1996 | 877 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2020 | 4758 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2019 | 6543 | 0.02 | Why? |
| Membrane Proteins | 1 | 2016 | 1733 | 0.02 | Why? |
| Survival Analysis | 1 | 2019 | 7592 | 0.02 | Why? |
| Aged, 80 and over | 3 | 2020 | 88759 | 0.02 | Why? |
| Factor X | 1 | 2004 | 18 | 0.02 | Why? |
| Crotalid Venoms | 1 | 2004 | 33 | 0.02 | Why? |
| Chronic Disease | 1 | 2019 | 5139 | 0.02 | Why? |
| Intubation, Intratracheal | 1 | 2020 | 3962 | 0.02 | Why? |
| Polymorphism, Restriction Fragment Length | 1 | 2004 | 116 | 0.02 | Why? |
| Survival Rate | 1 | 2019 | 9206 | 0.02 | Why? |
| Bone Marrow | 1 | 2006 | 492 | 0.02 | Why? |
| Lymphotoxin-alpha | 1 | 2001 | 15 | 0.01 | Why? |
| DNA Mutational Analysis | 1 | 2004 | 581 | 0.01 | Why? |
| Receptors, Interleukin-2 | 1 | 2001 | 115 | 0.01 | Why? |
| Genetic Testing | 1 | 2004 | 395 | 0.01 | Why? |
| Receptors, Interleukin-1 | 1 | 2001 | 161 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.01 | Why? |
| Osteoarthritis | 1 | 2001 | 205 | 0.01 | Why? |
| Interleukin-1 | 1 | 2001 | 438 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Time Factors | 1 | 2019 | 31397 | 0.01 | Why? |
| Interleukin-8 | 1 | 2001 | 964 | 0.01 | Why? |
| Child, Preschool | 1 | 2019 | 36283 | 0.01 | Why? |
| Neoplasm Invasiveness | 1 | 1996 | 582 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.01 | Why? |
| Acute Disease | 1 | 2006 | 6029 | 0.01 | Why? |
| Genotype | 1 | 2004 | 4697 | 0.01 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2001 | 2483 | 0.01 | Why? |
| Child | 1 | 2019 | 70012 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 2004 | 6740 | 0.01 | Why? |
| Predictive Value of Tests | 1 | 2004 | 9537 | 0.01 | Why? |
| Arthritis, Rheumatoid | 1 | 2001 | 2043 | 0.01 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 7868 | 0.00 | Why? |
| Sensitivity and Specificity | 1 | 2004 | 22971 | 0.00 | Why? |
HaznedaroGlu's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(207)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(57)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_